Abnormal involuntary movement scale in tardive dyskinesia: Minimal clinically important difference.

ABSTRACT:

Background

A minimal clinically important difference has not been established for the Abnormal Involuntary Movement Scale in patients with tardive dyskinesia. Valbenazine is a vesicular monoamine transporter 2 inhibitor approved for the treatment of tardive dyskinesia in adults. Efficacy in randomized, double-blind, placebo-controlled trials was defined as the change from baseline in Abnormal Involuntary Movement Scale total score (sum of items 1-7).

Objectives

To estimate an minimal clinically important difference for the Abnormal Involuntary Movement Scale using valbenazine trial data and an anchor-based method.

Methods

Data were pooled from three 6-week double-blind, placebo-controlled trials: KINECT (NCT01688037), KINECT 2 (NCT01733121), and KINECT 3 (NCT02274558)

SUBMITTER: Stacy M 

PROVIDER: S-EPMC6772010 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature